Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Schrödinger and Zai Lab have entered a global collaboration in precision oncology, focusing on a novel program targeting DNA damage response. This partnership aims to leverage Schrödinger's computational platform for drug discovery, with Zai Lab providing commercialization expertise. Under the agreement, Zai Lab will make an upfront payment to support research costs and will lead global development after selecting a candidate. Schrödinger could receive up to $338 million in milestone payments and royalties on global sales, enhancing its pipeline and potential market position.
Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) plans to report its financial results for Q2 2021 on August 9, 2021, after U.S. market close. A live conference call and webcast will occur on August 10, 2021, at 8:00 a.m. EDT. The company specializes in developing therapies for oncology, autoimmune disorders, and infectious diseases. With a solid pipeline and partnerships with leading biopharmaceutical companies, Zai Lab is focused on addressing unmet medical needs globally.
Zai Lab has entered a collaboration agreement with MacroGenics, acquiring rights for up to four bispecific molecules targeting cancer. Zai will commercialize these in Greater China, Japan, and Korea, while MacroGenics holds rights in other regions. The deal includes an upfront payment of $25 million and a $30 million equity investment in MacroGenics. Zai may convert the regional rights into a global profit share upon achieving clinical milestones. MacroGenics could receive up to $1.4 billion in milestone payments along with royalties on net sales.
Mirati Therapeutics and Zai Lab have entered a collaboration to develop and commercialize adagrasib, a KRASG12C inhibitor, in Greater China. Zai Lab secures rights for research, development, and commercialization, facilitating accelerated enrollment in pivotal clinical trials. Mirati receives a $65 million upfront payment with potential additional milestone payments totaling up to $273 million, plus tiered royalties. This collaboration aims to address the significant cancer prevalence in China, particularly lung cancer, enhancing patient access to innovative therapies.
Zai Lab has secured the rights to develop and exclusively commercialize adagrasib in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. This collaboration with Mirati Therapeutics involves an upfront payment of $65 million, milestone payments potentially totaling $273 million, and tiered royalties. The agreement aims to accelerate enrollment in global clinical trials for patients with KRASG12C mutations, targeting multiple cancer types including lung and colorectal cancers.
On May 28, 2021, Zai Lab Limited (NASDAQ: ZLAB) announced the dosing of the first patient in the registrational Phase 2 segment of the TRIDENT-1 study in China. This study evaluates repotrectinib for ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Repotrectinib aims to be a best-in-class treatment for these patients, showing promise due to its ability to address resistance to existing therapies. The FDA has granted various designations to repotrectinib, enhancing its development prospects in the oncology landscape.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has announced its participation in several virtual investor conferences in June 2021. The schedule includes a presentation at the Jefferies Healthcare Conference on June 2 at 10:00 a.m. EDT, a panel at the J.P. Morgan Global China Summit on June 3 at 10:45 a.m. HKT, and a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:50 a.m. EDT. Live webcasts will be available on the company’s website, along with archived replays for 90 days post-event.
Zai Lab Limited (NASDAQ: ZLAB) has announced the commencement of the METIS trial in Greater China, a Phase 3 pivotal study evaluating the efficacy of Tumor Treating Fields (TTFields) combined with radiosurgery for brain metastases from non-small cell lung cancer (NSCLC). This trial aims to enroll 270 patients, comparing the combination treatment against radiosurgery alone. With lung cancer being a leading cause of cancer incidence in China, this study addresses significant clinical needs. The primary endpoint is the time to cerebral progression, with secondary endpoints including overall survival.
Zai Lab Limited (NASDAQ: ZLAB) released its Q1 2021 financial results, reporting net product revenues of $20.1 million, up from $8.2 million year-over-year. Key highlights include the approval of QINLOCK for GIST in China and entering strategic collaborations enhancing its oncology and autoimmune portfolios. R&D expenses surged to $203.9 million due to significant upfront payments related to new partnerships. The company reported a net loss of $232.9 million or $2.64 per share, compared to a loss of $48.0 million or $0.66 per share in Q1 2020. Cash reserves stood at $1.01 billion as of March 31, 2021.